Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02012452 · ClinicalTrials.gov registry record · NA
Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD
A NA study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02012452: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT02012452 is a NA study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02012452, a NA study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to examine whether tobacco affects recovery from PTSD. There are 3 goals of the study; (1) to test if quitting tobacco prior to PTSD treatment affects treatment success, (2) to test how PTSD symptoms change in those who have quit tobacco compared to those who continue to use and (3) to explore how tobacco use and tobacco withdrawal symptoms change during PTSD treatment.
Primary Outcome
posttraumatic stress disorder clinician rated symptom ratings; scores range from 0-80 (with higher scores indicating greater PTSD severity)
Interventions
- BEHAVIORAL Health Education
- BEHAVIORAL Tobacco treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-01 |
| Phase | NA |
Why NCT02012452 stopped before completion
NCT02012452 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Health Education is the first listed.
NCT02012452 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02012452 about?
NCT02012452 is a clinical study titled "Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD". The purpose of this study is to examine whether tobacco affects recovery from PTSD. There are 3 goals of the study; (1) to test if quitting tobacco prior to PTSD treatment affects treatment success, (2) to test how PTSD symptoms change in those who have quit tobacco compared to those who continue to...
What is the current status of trial NCT02012452?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2014-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02012452?
The interventions under investigation include: Health Education (BEHAVIORAL), Tobacco treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02012452?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02012452's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia